Reviewer's report

Title: Health economics perspective of newly treating overactive bladder syndrome with fesoterodine, tolterodine or solifenacin in primary medical practice in Spain

Version: 1 Date: 4 September 2013

Reviewer: Oriol de Solà-Morales

Reviewer's report:

Minor essential revisions:

pg2: not background but Objectives
pg 4: line 2 a word is missing multicenter/multicentric

- there is no explanation on a major outcome, urinary frequency, volume, and there is no data of effectiveness of the different treatments beyond a Charlon adjustment.

- a larger explanation on the effect on results of a biased distribution of antidepressive treatments among the 3 different cohorts. To my understanding, the differences can justify the reduced need of visits. Furthermore, the differences in ADT may reflect different comorbidities not captured by the Charlson index, which is stated to be similar (that is an unacceptable way of referring to differences). It looks like some confounding factors may be overlooked in the analysis.

- authors state they cannot control/assess OAB severity amongst the cohorts, and that may affect level of resources required (i.e. results)

Minor:

- pg 6: a database is referred to, but no explanation of the source or structure or relevance of such database
- no reference on the difference between prescription and compliance, and how that may affect outcome
- costs are said to be adjusted to 2011 costs, but it is no clear how
- there is no evidence on which is the current standard of treatment, and which are the criteria to select treatment, and whether that can condition the choice of treatment. The relationship of that to the Charlson similarities and the idea that some confounding factors may be overlooked has to be further explained.

- a sensitivity analysis should be provided

Level of interest: An article whose findings are important to those with closely
related research interests

Quality of written English: Needs some language corrections before being published

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:
I declare that I have no competing interests